Brief: Eagle Pharmaceuticals Reports First Quarter 2023 Results
09/05/2023 11:52
May 9 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS REPORTS FIRST QUARTER 2023 RESULTS
* QTRLY EPS $0.44
* QTRLY ADJUSTED EPS $1.26
* REAFFIRMS FULL YEAR GUIDANCE
* EAGLE PHARMACEUTICALS - CASH AND CASH EQUIVALENTS WERE
$21.9
MILLION AS OF MARCH 31
* Q1 EARNINGS PER SHARE VIEW $1.05, REVENUE VIEW $63.3
MILLION --
REFINITIV IBES DATA
* FY2023 EARNINGS PER SHARE VIEW $4.21, REVENUE VIEW $262.5
MILLION -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX3H1KHg
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq